The nature of the GRE influences the screening for GR-activity enhancing modulators by Dendoncker, Karen et al.
RESEARCH ARTICLE
The nature of the GRE influences the
screening for GR-activity enhancing
modulators
Karen Dendoncker1,2, Steven Timmermans1,2, Kelly Van Looveren1,2, Lode De Cauwer3,4,
Karolien De Bosscher3,4, Claude Libert1,2*
1 Mouse Genetics in Inflammation, VIB Center for Inflammation Research, Ghent, Belgium, 2 Department of
Biomedical Molecular Biology, Ghent University, Ghent, Belgium, 3 Medical Biotechnology Center, VIB,
Ghent, Belgium, 4 Department of Biochemistry, Ghent University, Ghent, Belgium
* Claude.Libert@ugent.be
Abstract
Glucocorticoid resistance (GCR), i.e. unresponsiveness to the beneficial anti-inflammatory
activities of the glucocorticoid receptor (GR), poses a serious problem in the treatment of
inflammatory diseases. One possible solution to try and overcome GCR, is to identify mole-
cules that prevent or revert GCR by hyper-stimulating the biological activity of the GR. To
this purpose, we screened for compounds that potentiate the dexamethasone (Dex)-
induced transcriptional activity of GR. To monitor GR transcriptional activity, the screen was
performed using the lung epithelial cell line A549 in which a glucocorticoid responsive ele-
ment (GRE) coupled to a luciferase reporter gene construct was stably integrated. Histone
deacetylase inhibitors (HDACi) such as Vorinostat and Belinostat are two broad-spectrum
HDACi that strongly increased the Dex-induced luciferase expression in our screening sys-
tem. In sharp contrast herewith, results from a genome-wide transcriptome analysis of Dex-
induced transcripts using RNAseq, revealed that Belinostat impairs the ability of GR to
transactivate target genes. The stimulatory effect of Belinostat in the luciferase screen fur-
ther depends on the nature of the reporter construct. In conclusion, a profound discrepancy
was observed between HDACi effects on two different synthetic promoter-luciferase
reporter systems. The favorable effect of HDACi on gene expression should be evaluated
with care, when considering them as potential therapeutic agents. GEO accession number
GSE96649.
Introduction
Glucocorticoids (GC) are a most effective therapy for the treatment of many inflammatory
disorders, such as asthma, rheumatoid arthritis and inflammatory bowel disease [1–3]. Gluco-
corticoid actions are mediated by the glucocorticoid receptor (GR), a nuclear receptor. After
ligand binding, GR translocates to the nucleus where it performs functions as a monomer or
as a homodimer. By and large, the homodimer GR binds glucocorticoid responsive elements
(GRE) to activate gene expression while monomer GR interacts with pro-inflammatory
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transcription factors (NFκB and AP-1) to mediate gene repression [4]. Recent studies suggest
that besides GR monomers, also GR homodimers hold strong anti-inflammatory effects [5, 6],
via the induction of genes coding for anti-inflammatory proteins, such as MAPK phosphatase
1 (MKP1) [7] and GILZ [8].
The therapeutic success of GCs is limited due to two main drawbacks. High doses and/or
prolonged administration of synthetic GCs often result in side-effects, including glaucoma,
type 2 diabetes, growth retardation and skin thinning [9, 10]. Moreover, the occurrence of GC
irresponsiveness referred to as glucocorticoid resistance (GCR) hampers the success of GC-
based therapies [11, 12].
We have previously described that the inflammatory cytokine tumor necrosis factor (TNF),
both in vivo as well as in vitro using cell lines, induces a status of GCR [13]. We reasoned that a
screening for compounds that prevent or reverse GCR or that increase the transcriptional
capacity of GR dimers, may be beneficial for more efficient GR-based therapies [14, 15].
The access of transcription factors to gene promoters is regulated by epigenetic changes.
Histone acetyl transferases (HATs) coordinate the recruitment and activation of transcription
factors by acetylation of the histone tails, leading to unwinding of the chromatin and gene pro-
moter exposure. In their turn, histone deacetylases (HDACs) counteract the HAT activity,
which makes epigenetic changes highly dynamic and reversible [16–20]. Histones are not the
only targets of HDACs. Recent proteomics reports have shown that also non-histone proteins,
such as transcription factors, can be deacetylated by HDACs [21, 22]. This duality makes that
HDACs play multiple roles [23, 24] in the complex regulation of gene expression and signal
transduction [25–27], and regulate multiple biological processes such as cell differentiation,
survival and cell cycle progression [28].
Epigenetic changes are reversible and can be targeted by small molecules, such as HDAC
inhibitors (HDACi). Extensive research into novel HDACi [29] has resulted in series of diverse
modulators, each with their own target specificity and potency [30–32]. Originally HDACi
were used to treat solid and haematological cancers [33–36]. Nowadays, HDACi are used far
beyond the cancer field to treat, amongst others, neurodegenerative diseases [37, 38] and
inflammatory disorders [39, 40] such as rheumatoid arthritis [41], lupus erythematosus [42]
and type 2 diabetes [43]. So far, four HDACi, namely Vorinostat (SAHA), Romidepsin, Pano-
binostat and Belinostat, are approved by the United States Food and Drug Administration
(FDA). SAHA was the first approved drug in 2006 for the treatment of advanced cutaneous T-
cell lymphoma [44]. Vorinostat, along with Belinostat, approved for the treatment of patients
with relapsed or refractory T-cell lymphoma [45], are two pan-HDACi which can impair the
activity of both class I and II deacetylases [46].
Sepsis is an acute systemic inflammatory disease, which can be considered as a GC resistant
disease [47–50]. SAHA improves the survival in two rodent models of sepsis, namely lipopoly-
saccharide (LPS)-induced endotoxic shock [51] and the more clinical relevant model of cecal
ligation and puncture (CLP)-induced septic shock [52]. Although, so far these data are not
linked with the restoration of GR sensitivity, some HDACs influence the GR activity. HDAC6
for instance, acetylates Hsp90 and directly regulates the chaperone-mediated GR activation
[53]. Furthermore, GR deacetylation by HDAC2 is required for NFκB-mediated inflammatory
gene repression [54] and the acetylation status of HDAC1 dynamically modulates GR-induced
gene transcription [55].
We investigated the ability of 37 chemical compounds, including SAHA, MTA (histone
methylase inhibitor) and CPTH2 (HAT inhibitor) to increase the transcriptional activity of
GR in a luciferase-based reporter assay i.e. GRE-luc stably integrated in lung epithelial A549
cells which contain the GR protein endogenously. Increased luciferase activity following
enhanced expression levels, resulting from activated GR binding to glucocorticoid responsive
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elements (GREs), is a direct measure of the transcriptional activity of GR. We found that Vori-
nostat as well as Belinostat strongly induced the GR transcriptional activity as judged by a
GRE-luciferase reporter system. However, whole transcriptome analysis revealed that Belino-
stat in fact strongly impaired the transcriptional activity of GR, confirming the recent work of
Kadiyala [56]. After studying another GRE-driven reporter construct, i.e. the MMTV-lucifer-
ase reporter, we must conclude that, at least for the screening purposes of HDACi, results
obtained solely from the GRE-luciferase screening system must be interpreted with caution.
Materials and methods
Cell culture
A549 cells (lung epithelial cells) were maintained and grown in Dulbecco’s modified Eagle’s
medium (DMEM; house-made) containing 10% fetal calf serum (FCS), 1mM sodium pyru-
vate, 0,1mM non-essential amino acids, and 2mM L-glutamine.
Reagents and plasmids
The GRE-luc plasmid was described previously [57]. Briefly, the luciferase reporter construct
was driven by a synthetic GR-responsive promoter region containing two classic consensus
GRE sequences (underlined) derived from the tyrosine aminotransferase (TAT) gene pro-
moter AGATCTCTCTGCTGTACAGGATGTTCTAGCGGATCCTGCTGTACAGGATGTTCTAGCT
ACCTGCAG succeeded by a minimal IL6 promoter TATA box and followed by the luciferase
gene, of which the quantified luciferase expression is a direct measure of GR transcriptional
activity. The MMTV-luc (pGL4.36 [luc2P/MMTV/Hygro] Vector) plasmid was purchased
from Promega. SAHA (Vorinostat, SML0061) was obtained from Sigma Aldrich and Belino-
stat (PXD101, S1085), CI994, Class I HDACi (Tacedinaline, S2818) and Abexinostat, pan
HDACi, mostly targeting HDAC1 (PCI-24781) were purchased from Selleckchem. For all
compounds, a stock dilution of 10-2M was prepared in dimethylsulfoxide (DMSO) and stored
in -20˚C. Dexamethasone (Dex, D-2915) was purchased from Sigma Aldrich and dissolved in
water. Recombinant human TNF was produced in E. coli and purified in our department.
Transfection and reporter assays
X-tremeGENE HP DNA transfection reagent from Roche was used to transfect the A549
cells in 24-wells plate according to manufacturer’s instructions. Six hours after transfection
medium was changed to Optimem Medium (Gibco, Invitrogen) and cells were exposed to
HDACi. After the indicated duration, cells were stimulated with 10-6M Dex for five hours.
Cells were then harvested and luciferase activity, expressed in arbitrary light units, was quanti-
fied with the Glomax instrument, measuring the D-luciferin (L-1349, Duchefa) conversion.
For transiently transfected cells, luciferase activity was corrected for the protein concentration
in the sample by normalization to constitutive β-Gal levels. β-Gal levels were quantified with a
chemiluminescent reporter assay, using CPRG substrate (Sigma Aldrich).
RNA isolation and quantitative PCR
Total RNA was isolated from A549 cells using TRIzol (Gibco, Life Technologies) and the Invi-
Trap Spin Universal RNA Mini Kit (Invitek, Isogen Life Science) according to the manufactur-
er’s instructions. RNA concentration as measured with Nanodrop (Thermo Scientific), and
1μg of RNA was used to prepare cDNA by reverse transcription with the iScript advanced
cDNA synthesis kit (Bio-Rad). qPCR was performed with SYBR Green Master Mix (Bioline)
using the Roch LightCycler 480 system (Applied Biosystems). Luciferase mRNA was detected
Histone deacetylase inhibitor and luciferase reporter system
PLOS ONE | https://doi.org/10.1371/journal.pone.0181101 July 7, 2017 3 / 17
by RT-qPCR using the forward primer: 5’-ATACAAAGGATATCAGGTGG-3’ and the reverse
primer: 5’- TTGCGTCGAGTTTTCCGG-3’. Results are given as relative expression values
normalized to the geometric mean of the housekeeping genes 36B4 and Cyclophilin. The sta-
bility of these housekeeping genes in the appropriate experimental model and condition was
verified using the geNorm algorithm [58].
RNA sequencing
A549 cells were seeded in 6-well plates (0,5 x 106 cells/well) in DMEM. Cells were exposed to
Belinostat (1μM) equal dilution of DMSO, 16 hours before Dex (10-6M, five hours) or PBS
stimulation. Total RNA was isolated using TRIzol (Gibco Life Technologies) and the InviTrap
Spin Universal RNA Mini Kit (Invitek, Isogen Life Science) according to the manufacturer’s
instructions. RNA concentration was measured and quality was checked with the Agilent
RNA 6000 Pico Kit (Agilent Technologies Belgium), and 5μg of RNA was sent to the Nucleo-
mics core facility of VIB (http://www.nucleomics.be/) for sequencing on an Illumina Genome
Analyzer. Library preparation was performed according to the Illumina truseq RNA stranded
library protocol. The library was subjected to single end sequencing. Raw sequencing data
underwent a quality control analysis with FastQC [59]. To avoid low quality data the reads
were trimmed and filtered with Trimmomatic (version 0.33) [60]. Quality checked data were
mapped to the human reference genome (hg38; University of California, Santa Cruz) with
Tophat2 [61]. Read counts at the gene level were obtained with the Python tool htseq-count
[62] and differential gene expression was obtained using DESeq2. We used a false discovery
rate (FDR) of 1% and a log2 fold change |LFC| of 1 for comparisons to the control condition.
To detect subtler changes between Dex and Belinostat (single and co-treatment) the LFC cut-
off was lowered to 0.5 for the direct comparisons between these conditions (FDR was kept at
1%). RNAseq data are deposited under accession number GSE96649.
Statistical analysis
Except for Fig 1A, data were expressed as means ± standard errors of the means (SEM). Fold
changes were calculated by dividing the compound conditions by the proper DMSO control
condition and log (Y) transformation was applied before statistical analysis. Two-way ANOVA
was performed to test whether there was a difference between differential treatments. Subse-
quently, pairwise multiple comparisons based on the Tukey’s procedure was followed for post
hoc analysis to identify the differential compound/treatment. Obtained p-values are depicted
above the data points in the graphs.
For Fig 1A, a Generalized Linear Mixed Model (GLMM; fixed model: poisson distribution,
log link; random model: gamma distribution, log link) as implemented in Genstat v18 [63] has
been fitted to the absolute luciferase values of three compounds jointly, with compound–con-
centration set as fixed factor, and experiment as random term. T statistics were used to assess
the significance of all compound–concentration combination effects estimated as differences
(on the log-transformed scale) to the Dex-DMSO control.
Results
Belinostat strongly induces GRE-luciferase expression
The success rate of glucocorticoid therapy as a treatment for inflammatory disorders is limited
by side-effects and GCR [64, 65]. Screening for chemical compounds that ameliorate the GR
transcriptional output could be of great interest to circumvent both the side-effects and GCR.
Using stably transfected A549 human lung epithelial cells, we developed a GRE-luciferase
Histone deacetylase inhibitor and luciferase reporter system
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Fig 1. Belinostat strongly induces GRE-luciferase expression. (A) A549 cells, stably transfected with the GRE-luciferase plasmid, were exposed to
several inhibitors at different concentrations, 24h before Dex stimulation (10-6M for 5h). Data are shown as mean ± SEM (n = 2). A Generalized Linear
Mixed Model has been fitted to the luciferase values of the three compounds jointly obtained from two independent experiments, with compound–
concentration set as fixed factor, and experiment as random term. T statistics were used to assess the significance of all compound–concentration
combination effects estimated as differences (on the log-transformed scale) to the Dex-DMSO control (green dot). (B) Chemical structure of Belinostat
(C-D) Cells were treated with three different HDAC inhibitors 24h before (C) and 16h before (D) Dex stimulation and luciferase was measured 5h after
Dex stimulation. Data are shown as mean ± SEM (n = 3). One-way ANOVA of log (Y) transformed fold inductions (non-induced (NI) = 1, red dot) followed
by Dunnett’s multiple comparisons test were applied to compare each concentration of compound to the DMSO (Dex only) control (green dot). P-values
are depicted above the bars. (E) A549 cells were treated with different concentrations of Belinostat 24h, 16h and 6h before Dex (10-6M, 5h) stimulation or
together with Dex (0h pre-treatment). Fold inductions were obtained by dividing the compound condition by the proper non-induced, DMSO treated
condition per time point. Two-way ANOVA of log (Y) transformed fold inductions in combination with the Tukey test was performed to obtain statistical p-
values (n = 4). (F) 16h before TNF treatment, A549-GRE-luc cells were stimulated with 1μM Belinostat. GR activity was induced by 10-6M Dex given 1h
after TNF. Significant differences in Log (Y) transformed fold inductions were tested with two-way ANOVA and subsequently Sidak’s multiple
comparisons test (n = 4). The obtained p-values are reported.
https://doi.org/10.1371/journal.pone.0181101.g001
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reporter-based assay that measures the GR transcriptional activity and allows evaluating com-
pounds, at different concentrations and time points. In a first orienting screen, we tested a
small set of compounds, including inhibitors of several enzymes. A549-GRE-luc cells were
treated with a dilution series of compounds or DMSO, 24h prior to Dex stimulation (10-6M
for 5h). One compound, SAHA, known as a broad-spectrum HDAC inhibitor [66] strongly
augmented the Dex-stimulated and GRE-driven luciferase signal (Fig 1A), while other com-
pounds, e.g. the histone methylase inhibitor MTA and the HAT inhibitor, CPTH2, had no
effect. We next explored the effect of additional HDAC inhibitors in the assay, namely the
pan-HDAC inhibitors Abexinostat and Belinostat and the HDAC class I-specific CI994.
A549-GRE-luc cells were exposed to these inhibitors 24h as well as 16h prior to Dex treatment
(Fig 1C and 1D respectively). Dex-induced luciferase expression was divided by the non-
induced expression to obtain the fold induction. The impact of the compounds on the fold
induction is displayed. The effect of Belinostat alone on the luciferase expression was not tested
in the first screening in Fig 1. However, as will be clear later on in the paper, Belinostat already
induces the GRE-luc system in the absence of Dex especially when cells are pre-treated for a
long time. The maximal GR transcriptional activity was observed after 16h pre-treatment of
inhibitor. With a 4.1 fold higher luc signal compared to Dex-DMSO, the broad spectrum
HDAC inhibitor Belinostat (structure see Fig 1B) was selected for further follow-up. Belinostat
also has the additional advantage of being an FDA approved drug. Based on concentration-
response and kinetics studies (see Fig 1E), we found that pre-incubation of 16h of 1μM Belino-
stat was the optimal condition to proceed. Next, the potential of this Belinostat treatment was
tested in a TNF-induced glucocorticoid resistance model. When A549-GRE-luc cells are
treated with TNF, 1h before Dex stimulation, the GR transcriptional activity is strongly
reduced (Fig 1F). This result correlates with the findings of Van Bogaert et all. who demon-
strated GCR in vivo [67]. Interestingly, in the GCR condition, Belinostat pre-treatment induces
the GR activity in such a way that the luciferase levels are significantly higher compared to the
DMSO–Dex condition. Although, the GCR still occurs in presence of Belinostat, suggesting
that Belinostat interferes with the GR activity, rather than with the mechanism that leads to
TNF-induced GCR.
Belinostat impairs the Dex-induced expression of GR target genes
To next study the impact of Belinostat on endogenous GR-induced (GRE-driven) genes, we
performed a transcriptome profiling using RNA sequencing in A549 cells. The impact of a 5h
incubation of 10-6M Dex on the transcriptome of A549 cells was significant, and numerous
GRE genes were strongly induced, e.g. FKBP5 (21-fold induction) and SGK (4.89-fold induc-
tion). In total, 938 genes were strongly and significantly affected by Dex (S1 Table), i.e. with a |
LFC| 1; FDR: 1% of which 610 were upregulated and 328 were downregulated by Dex. Beli-
nostat by itself was found to already have a large effect on the gene expression profile: 5082
genes were significantly differentially expressed (S2 Table) (|LFC| 1; FDR: 1%) following a
16h Belinostat treatment at 1μM (2934 up, 2148 down).
To validate the GRE-luciferase assay result on a genome-wide scale, we studied the influ-
ence of Belinostat and Dex co-treatment on the subset of Dex-regulated genes. Only a minority
of these genes are higher expressed by Belinostat together with Dex, compared to Dex alone.
Fig 2 shows that for both Dex-upregulated (A) and Dex-downregulated (B) genes, the subset
of genes on which the effect of Dex is enhanced by Belinostat treatment is smaller than the group
of genes on which Belinostat has no effect or counteracts the Dex effect. Out of the 610 Dex-
upregulated genes (LFC 1; FDR: 1%) only 115, (18.8%), are further upregulated by Belinostat
co-treatment (LFC 0.5; FDR: 1%). For downregulated genes, only 63 (19.2%) out of the 328
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are affected by Belinostat in a positive way (i.e. stronger downregulation). The majority of the
genes is adversely affected by the co-treatment compared to Dex alone: 332 Dex-upregulated
Fig 2. Belinostat impairs Dex-induced expression of GR target genes. A549 cells were exposed to Belinostat (1μM) or DMSO (same dilution)
for 16h before Dex stimulation (10-6M, 5h) (n = 3). Data were obtained from an expression profiling performed by means of RNA-seq. (A) Effect of
Belinostat pre-treatment on the expression of Dex-induced genes. The majority of genes are negatively affected (i.e. less upregulated) compared to
Dex only treatment (LFC < -0.5; FDR: 1%; Dex and Belinostat vs Dex). Less than one fifth (18.85%) of all Dex-induced genes are positively affected
by Belinostat (LFC > 0.5; FDR: 1%; Dex and Belinostat vs Dex). (B) Effect of Belinostat pre-treatment on the expression of Dex-inhibited genes. The
majority of genes are negatively affected (i.e. less downregulated) compared to Dex only treatment. About one fifth (19.21%) of all Dex inhibited
genes are more inhibited by Belinostat. (C) Box-and-whisker plots, with the box comprising the 25–75 percentile and the whiskers the 5–95
percentile range of the log2 transformed normalized counts from the 115 Dex-induced genes positively affected by Belinostat. One-way ANOVA of
log2 transformed counts was applied for analysis of statistical significance. ns, not significant. Without any treatment, the median expression of
these genes is the lowest. Either Dex or Belinostat alone can cause a significant upregulation of these genes. The co-treatment condition causes the
median expression level to be significantly higher than what can be done by Dex alone, but there is no significant difference with the Belinostat only
treatment, i.e. the Belinostat treatment is the dominant effect. (D) In order to exclude Belinostat only (or Belinostat dominant) genes that showed a
significant effect of Belinostat only treatment, were removed from (A) and (B). When this correction is applied, only 5 Dex-regulated genes are
positively affected by Belinostat (of 290), showing that the positive effect of Belinostat is greatly outweighed by its negative effect.
https://doi.org/10.1371/journal.pone.0181101.g002
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genes (54.4%) and 153 Dex-downregulated genes (46.6%) are in this group. Because of the
genome-wide effect of Belinostat alone, Belinostat affects also the expression of many GR-inde-
pendent genes. In addition, in many of the cases where Belinostat exerts an agonistic effect, the
effect is that of Belinostat alone: there is no significant difference between Belinostat alone and
the co-treatment of Dex and Belinostat (Fig 2C). To exclude these Belinostat-only effects, we
excluded genes that were differentially expressed by Belinostat alone, i.e. genes that are regulated
independent of GR activity. After this filtering step, 290 Dex-regulated genes were left to con-
sider (out of 938 genes differentially expressed by Dex) (Fig 2D). Hereof, the majority (276
genes) were adversely affected by Belinostat; nine genes showed no effect of Belinostat treatment
and only 5 genes showed evidence of a positive influence by Belinostat on the effect mediated by
Dex. We conclude that Belinostat treatment is clearly the dominant factor in the co-treatment
and that there is little evidence for a co-operation between Dex and Belinostat treatment.
No difference of Belinostat stimulation on stably and transiently
transfected GRE-luc reporter
HATs and HDACs dynamically and reversible regulate the chromatin compaction along
the genome and so HDACi are expected to have an impact on chromatin condensation and
transcription factor accessibility to promoter regions. To exclude that the opposite findings
between the luciferase assay and the RNAseq are caused by an effect of Belinostat on the region
surrounding the GRE-luc integration site, rather than on GRE-luc itself, the impact of Belino-
stat on an exogenous GRE-luc plasmid was investigated.
The effect of Belinostat on the luciferase expression of stably and transiently transfected
reporter constructs was compared in Fig 3. Belinostat stimulated Dex-induced luciferase
expression in stably as well as transiently transfected A549 cells, ruling out that the positive
effect of Belinostat on the luciferase expression is influenced by the specific integration site of
the plasmid in the stable cells.
Fig 3. No difference of Belinostat stimulation on stably and transiently transfected GRE-luc reporter.
A549 cells were transiently or stably transfected with the GRE-luciferase reporter plasmid, respectively left or
right panel. Belinostat (1μM) or DMSO (same dilution) were exposed 16h before Dex stimulation (10-6M, 5h).
The results are represented as fold inductions relative to the control (non-induced), mean ± SEM. Two-way
ANOVA of log (Y) transformed fold inductions in combination with Tukey’s multiple comparisons test were
applied for analysis of statistical significance, P-values are depicted (n = 3).
https://doi.org/10.1371/journal.pone.0181101.g003
Histone deacetylase inhibitor and luciferase reporter system
PLOS ONE | https://doi.org/10.1371/journal.pone.0181101 July 7, 2017 8 / 17
Belinostat has no direct impact on luciferase biological activity
The compound screening was performed in cells using a previously described luciferase
reporter construct under influence of a synthetic GR-responsive promoter region with GRE
sequences. These sequences were derived from the TAT promoter [57] driving the expression
of the heterologous luciferase gene, of which the quantified luciferase expression is a direct
measure of GR transcriptional activity. Reporter gene-based systems, depending on an enzy-
matic read-out, have to be considered with care, since the stability and activity of the gene
product can be influenced by the treatment leading to potentially misleading conclusions. We
measured luciferase mRNA levels after Belinostat treatment in A549-GRE-luc cells, to confirm
that Belinostat modulates GR-mediated luciferase mRNA induction, not protein stability or
activity. Cells were exposed to Belinostat either 24h or 16h prior to Dex, or simultaneously
with Dex, and RNA was extracted from the cells five hours after Dex. The relative luciferase
mRNA expression (Fig 4A) demonstrates that Belinostat induces luciferase expression at the
mRNA level, illustrating the ability of Belinostat to activate transcription of the GRE-contain-
ing promoter. Remarkably, Belinostat was also able to induce luciferase mRNA expression
independent of the presence of the GR ligand Dex. We believe that in absence of ligand, some
leak expression is observed with Belinostat, due to a more open chromatin state. Indeed, inhi-
bition of HDACs leads to an enhanced chromatin acetylation, which relax the chromatin and
make it accessible for pioneering transcription factors. Furthermore, upon adding 1μM Beli-
nostat to lysates of A549 cells, previously stimulated with Dex, before luciferase measurement
no stimulatory effect on luciferase readout was observed, confirming that Belinostat does not
influence the activity and stability of the luciferase protein (Fig 4B).
The Effect of Belinostat depends on the nature of the GRE-dependent
promoter construct
As shown in Fig 4, Belinostat had stimulatory effects on the Dex-stimulated and TAT pro-
moter-derived GRE-luciferase, stably transfected in A549 cells [57]. The MMTV-luc vector con-
tains the MMTV-LTR (Murine Mammary Tumor Virus Long Terminal repeat) that drives the
transcription of the luciferase reporter gene in response to activation of GR. This MMTV-LTR
contains six TGTTCT GR responsive half-sites [68]. This reporter, when studied in A549 cells
Fig 4. Belinostat does not influence the enzymatic activity of the luciferase protein. (A) A549 cells were exposed to Belinostat (1μM) or
DMSO (same dilution) for 24h or 16h before Dex stimulation (10-6M, 5h) or together with Dex. Cells were harvested at 5h after Dex stimulation. RNA
was isolated and subjected to RT-qPCR to measure luciferase mRNA expression. (B) After the five hours during Dex stimulation (10-6M, 5h), A549
cells were lysed in lysis buffer supplemented with 1μM Belinostat (left panel). In the right panel, Belinostat was added 16h before Dex stimulation
(n = 3). Statistical significance in (A) and (B) was proven by two-way ANOVA and Tukey’s multiple comparison test on log (Y) transformed data.
https://doi.org/10.1371/journal.pone.0181101.g004
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upon transient transfection, responds to Dex (10-6M, 5h), but no stimulatory effects of Belino-
stat (1μM, 16h pre-treatment) were observed in the absence or presence of Dex. On the con-
trary, Belinostat reduces the luciferase expression (Fig 5). To conclude, the effect of Belinostat
on the transcriptional activity of GR heavily depends on the nature of the GRE-driven reporter
constructs, with an enhancement of Belinostat on a GR-driven consensus GRE-luc and a dimi-
nution of Belinostat on a half-site GRE dependent MMTV-luc.
Discussion
GCs are potent anti-inflammatory molecules. It is estimated that at least 80 million prescrip-
tions per year in the USA deal with GCs [8]. They are cheap and efficient and found in pills,
creams, inhalators, etc. Despite their overall success, doctors and patients are concerned about
two negative aspects. First, long term treatment of GCs leads to serious side-effects. Second,
large patient groups display a certain degree of GCR [64]. This GCR is related to the degree of
inflammation and numerous in vitro and in vivo studies have investigated the mechanism
underlying GCR. Several hypotheses have been described. In mouse models, inflammatory
cytokines such as TNF, when injected, lead to a strong and acute GCR [13].
Hundreds of genes have been identified as GRE-dependent genes and are known to be reg-
ulated by GCs. In many cases, one or more GRE elements can be coupled to a transcript, based
on genome-wide GR binding experiments, but many transcripts have not yet been associated
to a GRE element and, conversely, not all GRE elements found in the genome are bound by
GR [69]. It is clear that there are number of regulation steps involved in the choice of GRE ele-
ments to be bound by GR and in his specific outcome after GRE binding. It is known that par-
ticular DNA sequences can modify the structure and function of transcriptional regulators as
if they were a ligand, as postulated by Lefstin and Yamamoto [70]. The expression from a con-
sensus GRE or a GRE half-site has a distinct regulation, as stated by the fact that dimerization-
defective GR mutants are unable to express the TAT gene, although PNMT expression is nor-
mal [71].
Fig 5. The Effect of Belinostat depends on the nature of the GRE-dependent promoter construct. A549 cells were
transiently transfected with MMTV-luc and β-Gal and stimulated with 1μM Belinostat, 16h before Dex treatment (10-6M,
5h). Transcriptional activities, normalized against β-Gal expression ± SEM (n = 6).
https://doi.org/10.1371/journal.pone.0181101.g005
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HDACs have been linked to GR and other nuclear receptors and transcription factors as
they perform repressive activities by reverting histone acetylation. Some papers report that
HDACs are also required for transcriptional activity. HDAC6 for instance, acetylates Hsp90
and directly regulates the chaperone-mediated GR activation [53]. HDAC3 acetylates NFκB
and consequently stimulates the IL-1-induced gene expression, being a co-activator in inflam-
matory signaling pathway [25, 72]. On the other hand, reduction in HDAC2 expression and
activity leads to enhanced inflammation and reduced steroid responsiveness in chronic
obstructive pulmonary disease (COPD) [73]. It has been proven that GR deacetylation by
HDAC2 is necessary for suppression of NFκB-mediated inflammatory gene expression, but
not for the GRE-mediated gene expression [54]. GR-induced gene transcription is dynamically
modulated by the HDAC1 acetylation state. The necessity of HDAC1 as coactivator for GR
was first proven for the MMTV gene [55] and later on for the entire GR transcriptome [56].
Since inhibition of HDACs may stimulate transcriptional activity of transcription factors,
several HDACs have been studied in detail and numerous HDAC inhibiting drugs have been
developed. Some of these broad spectrum HDAC inhibitors have been approved for clinical
use in several types of cancers.
We and others have shown before that under TNF-induced GCR conditions, the transcrip-
tional activity of GR is heavily compromised [13]. One way of preventing or reverting GCR
might be to search for molecules that stimulate GR transcriptionally activity so that even
under GCR conditions, GCs, in combination with such a stimulator, would reach sufficient
levels of GR activity. In this respect, we embarked on a screening of chemical compounds
using a simple in vitro system, consisting of lung epithelial A549 cells, stably transfected with a
GRE-luciferase reporter system. Of course, our results and conclusions must be considered
within the experimental limits set by the A549 cell line, including its aneuploidies, epigenome,
differentiation status, etc. A549 is a very validated cell line, but there is indeed no guarantee
that our conclusions (like those of other authors), would still stand in other experimental
system.
Based on our screening with A549-GRE-luc cells, it was clear that a number of broad spec-
trum HDAC inhibitory molecules, such as Belinostat, displayed a strong co-stimulatory effect
with Dex, especially with a pre-treatment schedule. The long time course of Belinostat pre-
treatment may suggest indirect effects mediated by the altered expression or acetylation of one
or more component(s) of the glucocorticoid signaling pathway. The maximal luciferase fold
induction obtained with Dex alone (10-6M) was increased about four- to ten-fold (Fig 1C).
When studying the impact of Belinostat on a genome-wide scale, only a minority of Dex-
induced genes was further enhanced in the presence of Belinostat, or more repressed in case of
Dex repressed genes. Belinostat alone had a huge effect on the mRNA levels of thousands of
genes. When taking the impact of Belinostat into consideration on Dex-regulated genes with-
out basal Belinostat effect, only 5 genes were found to be further regulated in the same direc-
tion by Belinostat (Fig 2D). Among them, the SAA1 gene contains a GRE like match in the
promoter (AGATCACTCTGTGCA). We also checked the genes that did show a basal effect of
Belinostat alone with a Dex effect for GRE elements and surrounding sequence. However, we
could not find GRE elements any more than could be expected by random chance in these
groups. Hence, the RNAseq experiment did not correlate in a direct manner to the reporter-
based assay. We subsequently investigated several mechanisms that could explain the contra-
dictory effects of Belinostat including the chromatin status, as transformed GRE-luc, inte-
grated in the A549 genome is accepted to be wrapped around histones. These histones contain
an N-terminal histone tail which can undergo posttranslational modifications including lysine
ubiquitination, sumoylation, phosphorylation but also acetylation [74]. The last one is dynami-
cally modulated by histone acetyltransferases (HAT) and histone deacetylases (HDAC).
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Acetylated lysines are bound by bromodomains, which are often found in HATs and chroma-
tin remodelling complexes, such as the SWI/SNF complex, which open the chromatin and reg-
ulate transcription [75]. HDACi are thought to interfere with transcription by modulating the
histone acetylation state. On the other hand, recent studies showed that HDACs could also
deacetylate non-histone proteins, such as transcription factors [21, 22]. The transient GRE-luc
assay was performed to investigate the role of Belinostat on non-histone proteins since tran-
siently transfected plasmids are not integrated in the genome and aren’t prone to chromatin
remodelling. Hence, these findings support the observation that the beneficial effects of Belino-
stat on the GRE-induction are not caused by histone modifications of target promoters or
depends on the genomic integration site of the reporter but rather by effects on components of
the GR signalling pathway including nuclear cofactors that link GR with the transcriptional
machinery. We investigated the effect of SAHA and Belinostat treatment on GR acetylation,
but could not detect any difference in acetylation after HDACi treatment (data not shown),
suggesting the involvement of proteins others than GR. Furthermore, the impact of Belinostat
on the GRE-luciferase system appeared to be at the level of transcription of the luciferase gene,
not on luciferase protein stability or activity. Remarkably, in accordance with the RNAseq
data, Belinostat enhances the luciferase expression in absence of GR ligand. We believe that
this leakage expression is caused by histone modification and chromatin opening, which favors
luciferase expression in absence of activated GR. Although, after Dex stimulation, the main
mechanism of which Belinostat exerts its effects is thought to be mediated via components of
the GR signalling pathway.
Finally, by testing Belinostat effects in another, and differentially regulated validated GC
reporter system, i.e. the MMTV-luciferase reporter, no co-stimulatory effect of Belinostat was
observed, but on the contrary, a repressive effect was seen. Although additional experiments
will be needed to further pinpoint the exact mechanisms of action of Belinostat on the GRE-
luc and MMTV-luc reporter construct, it is of interest that signalling pathways involving dif-
ferent GR responsive elements can be modulated differentially by Belinostat. We have consid-
ered a possible mechanism by which Belinostat have an altered effect on GRE-luc and MMTV-
luc expression. It has been proposed that the bound DNA sequence acts as an allosteric ligand
that alters GR conformation and hence interactions with other proteins such as cofactors
which ultimately affect the transcriptional output [76]. Consequently, the sequence of the pal-
indromic GRE site have strong implications for the composition and structure of the regula-
tory complexes and the mechanisms of context-specific transcriptional regulation [77].
Therefore, we suggest that the differential outcome on GRE-luc and MMTV-luc of a Belinostat
treatment is due to a different impact of Belinostat on each cofactor profile. Blind et al. demon-
strated that the histone acetyltransferase p300 is recruited to the TAT-GRE promoter in a Dex
responsive way, indicating a role of p300 in GR transcriptional activity [78]. On the other
hand, Qiu et al identified HDAC1 as coactivator for GR-induced transcription of the MMTV
promoter [79]. More specifically, the acetylation state of HDAC1 with the activity state of the
promoter and affects the exchange rate of HDAC1 at the promoter site. This indicates that
HDACi may affect this acetylation status and consequently negatively regulate MMTV expres-
sion. Taken together, the GR binding sequence in the promoter region modulates the GR con-
formation which attracts different nuclear cofactors depending on the promoter context.
These nuclear TFs contain chromatin remodeling activities and are prone to HDAC/HAT
activities. They link the GR to the transcriptional machinery and affect gene regulation. One
additional note, as seen by ChIPseq, GR binding sites are often located far from promoter
regions and transcription start sites, suggesting that responsive elements can loop towards pro-
moter regions of target genes in order to regulate transcription [80]. These looping events are
mediated by a large nuclear protein complex which is prone to additional post-translational
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modifications. The synthetic reporter constructs GRE-luc and MMTV-luc contain the GR
binding site closely to their promoter, which make looping unnecessary. This difference in reg-
ulation between endogenous genes and the luciferase gene might be an additional reason for
the difference in results of the screening assay and the RNAseq.
Our work has contributed to identify opposite GRE-specific regulatory effects by the
HDACi Belinostat, with a stimulatory effect on the classic palindromic GRE derived from the
TAT promoter and an inhibitory effect on the specific GRE from the MMTV promoter. To
extract generalizing conclusions based on reporter gene assays, our take-home message would
be to not solely rely on one type of promoter-luciferase reporter, but invest in different ones
and also invest in non-reporter dependent validation assays.
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